Brought to you by 
Synlogic closes $42mm Series C financing
16 May 2017
Executive Summary
Synlogic Inc. raised $42mm through a Series C preferred stock financing to first-time backers Aju IB Investment, Ally Bridge Group, Arctic Aurora LifeScience, CLI Ventures, Perceptive Advisors, Rock Springs Capital, and other undisclosed new investors, which were joined by returning shareholders Atlas Venture, Deerfield, New Enterprise Associates, and OrbiMed. The financing was concurrent with the company announcing it is reverse merging with publicly traded Mirna Therapeutics Inc. The funds will enable Synlogic to move its lead metabolic programs through proof-of-concept and also develop early-stage candidates. Leerink Parnters was the placement agent.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Synlogic closes $42mm Series C financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice